CA2255826A1 - Mutated nonactivating igg2 domains and anti-cd3 antibodies incorporating the same - Google Patents

Mutated nonactivating igg2 domains and anti-cd3 antibodies incorporating the same

Info

Publication number
CA2255826A1
CA2255826A1 CA002255826A CA2255826A CA2255826A1 CA 2255826 A1 CA2255826 A1 CA 2255826A1 CA 002255826 A CA002255826 A CA 002255826A CA 2255826 A CA2255826 A CA 2255826A CA 2255826 A1 CA2255826 A1 CA 2255826A1
Authority
CA
Canada
Prior art keywords
antibodies
same
mutated
nonactivating
antibodies incorporating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002255826A
Other languages
French (fr)
Other versions
CA2255826C (en
Inventor
J. Yun Tso
Michael S. Cole
Claudio Anasetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Biotherapeutics Inc
Fred Hutchinson Cancer Center
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2255826A1 publication Critical patent/CA2255826A1/en
Application granted granted Critical
Publication of CA2255826C publication Critical patent/CA2255826C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The invention provides mutated IgG2 constant regions and anti-CD3 antibodies incorporating the same. Such antibodies specifically bind to the CD3 antigen on T-cells but induce reduced mitogenic response compared with otherwise identical antibodies bearing natural IgG2 constant regions. The antibodies can be used for treating disorders requiring immune suppression with fewer side effects than result from treatment with prior anti-CD3 antibodies.
CA002255826A 1996-05-20 1997-05-19 Mutated nonactivating igg2 domains and anti-cd3 antibodies incorporating the same Expired - Lifetime CA2255826C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US65041096A 1996-05-20 1996-05-20
US08/650,410 1996-05-20
US08/656,586 1996-05-31
US08/656,586 US5834597A (en) 1996-05-20 1996-05-31 Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
PCT/US1997/008576 WO1997044362A1 (en) 1996-05-20 1997-05-19 MUTATED NONACTIVATING IgG2 DOMAINS AND ANTI-CD3 ANTIBODIES INCORPORATING THE SAME

Publications (2)

Publication Number Publication Date
CA2255826A1 true CA2255826A1 (en) 1997-11-27
CA2255826C CA2255826C (en) 2002-10-01

Family

ID=27095860

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002255826A Expired - Lifetime CA2255826C (en) 1996-05-20 1997-05-19 Mutated nonactivating igg2 domains and anti-cd3 antibodies incorporating the same

Country Status (11)

Country Link
US (1) US5834597A (en)
EP (1) EP0966485B1 (en)
JP (2) JP3947570B2 (en)
CN (1) CN100549031C (en)
AT (1) ATE407952T1 (en)
AU (1) AU725821B2 (en)
CA (1) CA2255826C (en)
DE (1) DE69738984D1 (en)
ES (1) ES2313736T3 (en)
PT (1) PT966485E (en)
WO (1) WO1997044362A1 (en)

Families Citing this family (301)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
AU7467898A (en) * 1997-04-21 1998-11-13 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
PT1068241E (en) * 1998-04-02 2007-11-19 Genentech Inc Antibody variants and fragments thereof
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
EP2364997A3 (en) * 1999-01-15 2012-07-04 Genentech, Inc. Polypeptide variants with altered effector function
DE19905012A1 (en) * 1999-02-08 2000-08-10 Gsf Forschungszentrum Umwelt Medicines containing anti-CD3 and anti-Fcgamma-R antibodies for accompanying treatment in organ transplants
DE19905048A1 (en) * 1999-02-08 2000-08-10 Gsf Forschungszentrum Umwelt Use of depletoric or mitogenic antibodies in immunotherapy
BR0008209A (en) * 1999-02-12 2002-02-19 Genetics Inst Humanized immunoglobulin reactive with b7 molecules and treatment processes with them
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
EP1085453A1 (en) * 1999-09-20 2001-03-21 TELEFONAKTIEBOLAGET LM ERICSSON (publ) SIM card holder
KR20110032012A (en) 2000-02-10 2011-03-29 아보트 러보러터리즈 Antibodies that bind human interleukin-18 and methods of making and using
IL151348A0 (en) 2000-04-13 2003-04-10 Univ Rockefeller Enhancement of antibody-mediated immune responses
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
GB2380127A (en) * 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
DE60226641D1 (en) * 2001-12-03 2008-06-26 Amgen Fremont Inc ANTIBODY CATEGORIZATION BASED ON BINDING CHARACTERISTICS
AU2002357779A1 (en) * 2001-12-03 2003-06-17 Abgenix, Inc. Identification of high affinity molecules by limited dilution screening
EP1466177A4 (en) * 2001-12-03 2005-08-17 Abgenix Inc Discovery of therapeutic products
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20030216551A1 (en) * 2002-03-08 2003-11-20 Diabetogen Biosciences Inc. Fully human anti-CD3 monoclonal antibodies
SE0200943D0 (en) * 2002-03-25 2002-03-25 Amersham Biosciences Ab Mutant protein
EP1499352A4 (en) * 2002-04-12 2006-10-11 Medimmune Inc Recombinant anti-interleukin-9 antibodies
WO2003101485A1 (en) * 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
WO2003105896A1 (en) * 2002-06-14 2003-12-24 Novo Nordisk A/S Combined use of a modulator of cd3 and a beta cell resting compound
US20040037826A1 (en) * 2002-06-14 2004-02-26 Michelsen Birgitte Koch Combined use of a modulator of CD3 and a GLP-1 compound
EP1515749B1 (en) * 2002-06-14 2012-08-15 Novo Nordisk A/S Combined use of a modulator of cd3 and a glp-1 compound
AU2003253621A1 (en) * 2002-06-14 2003-12-31 Centocor, Inc. Modified "s" antibodies
US20030235583A1 (en) * 2002-06-14 2003-12-25 Jeppe Sturis Combined use of a modulator of CD3 and a beta cell resting compound
AR040778A1 (en) * 2002-08-06 2005-04-20 Glaxo Group Ltd ALTERED ANTIBODIES OR FUNCTIONAL FRAGMENTS THAT BIND MAG (GLICOPROTEIN ASSOCIATED WITH HONEY).
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) * 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP2006511620A (en) * 2002-12-05 2006-04-06 プロテイン デザイン ラブス インコーポレイティド Method for treating ulcerative colitis with anti-CD3 antibody
PT1572748E (en) * 2002-12-17 2010-09-28 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1596813A4 (en) * 2003-01-31 2008-02-20 Five Prime Therapeutics Inc Lung-expressed polypeptides
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
CN1798767B (en) * 2003-04-10 2011-02-16 晶面生物技术公司 Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
KR20110094361A (en) * 2003-04-11 2011-08-23 메디뮨 엘엘씨 Recombinant il-9 antibodies and uses thereof
CU23403A1 (en) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular RECOMBINANT ANTIBODIES AND FRAGMENTS RECOGNIZING GANGLIOSIDE N-GLICOLIL GM3 AND ITS USE FOR DIAGNOSIS AND TUMOR TREATMENT
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
JP5068072B2 (en) * 2003-06-27 2012-11-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド Modified binding molecule comprising a linking peptide
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
CA2545539A1 (en) * 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
CA2545806C (en) * 2003-11-14 2014-09-16 Brigham And Women's Hospital, Inc. Methods of modulating immunity
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
EP1725254A4 (en) * 2004-02-04 2008-02-13 Univ Columbia Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity
EP2053062A1 (en) * 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
KR20070039911A (en) * 2004-06-01 2007-04-13 도만티스 리미티드 Bispecific fusion antibodies with enhanced serum half-life
BRPI0510883B8 (en) 2004-06-01 2021-05-25 Genentech Inc drug-antibody conjugate compound, pharmaceutical composition, method of manufacturing a drug-antibody conjugate compound, and uses of a formulation, a drug-antibody conjugate and a chemotherapeutic agent, and a combination
ES2526343T3 (en) 2004-06-03 2015-01-09 Novimmune Sa Anti-CD3 antibodies and methods of use thereof
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
DK1776384T3 (en) 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT Fc REGIONS
WO2006031994A2 (en) * 2004-09-14 2006-03-23 Xencor, Inc. Monomeric immunoglobulin fc domains
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2006053301A2 (en) 2004-11-12 2006-05-18 Xencor, Inc. Fc variants with altered binding to fcrn
NZ555464A (en) 2004-12-02 2010-03-26 Domantis Ltd Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
NO346624B1 (en) 2004-12-28 2022-11-07 Univ Di Genova Monoclonal antibody against NKG2A
WO2006076594A2 (en) * 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
AU2006218876A1 (en) * 2005-02-28 2006-09-08 Centocor, Inc. Heterodimeric protein binding compositions
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2707152T3 (en) 2005-04-15 2019-04-02 Macrogenics Inc Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
CA2618681C (en) 2005-08-10 2015-10-27 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
UA92505C2 (en) * 2005-09-12 2010-11-10 Новиммюн С.А. Anti-cd3 antibody formulations
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
AU2006302254B2 (en) 2005-10-06 2011-05-26 Xencor, Inc. Optimized anti-CD30 antibodies
AR059922A1 (en) 2006-04-01 2008-05-07 Galaxy Biotech Llc HUMANIZED MONOCLONAL ANTIBODIES FOR THE GROWTH FACTOR OF HEPATOCITS
US7786270B2 (en) 2006-05-26 2010-08-31 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
CA2652945C (en) 2006-05-30 2015-06-02 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
AU2007258694B2 (en) * 2006-06-06 2011-12-22 Glaxo Group Limited Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
BRPI0713426A2 (en) 2006-06-14 2012-10-09 Macrogenics Inc methods of treating, slowing the progression, or ameliorating one or more symptoms of a disorder, and preventing or delaying the onset of a disorder
SI2029173T1 (en) 2006-06-26 2016-12-30 Macrogenics, Inc. Fc riib-specific antibodies and methods of use thereof
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
RS53263B (en) 2006-08-14 2014-08-29 Xencor Inc. Optimized antibodies that target cd19
AU2007299843B2 (en) 2006-09-18 2012-03-08 Xencor, Inc Optimized antibodies that target HM1.24
WO2008055072A2 (en) 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
PT2502938E (en) 2006-10-27 2015-06-05 Genentech Inc Antibodies and immunoconjugates and uses therefor
MX2009004532A (en) 2006-10-27 2009-09-04 Lpath Inc Compositions and methods for binding sphingosine-1-phosphate.
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
CN103709249B (en) * 2006-12-20 2016-02-24 Mmr全球公司 Antibody and preparation and application thereof
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
DK2164992T3 (en) * 2007-05-30 2016-08-15 Lpath Inc COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
PE20140196A1 (en) 2007-08-09 2014-03-19 Boehringer Ingelheim Int ANTI-CD37 ANTIBODIES
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
US8795667B2 (en) 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
SI2808343T1 (en) 2007-12-26 2019-10-30 Xencor Inc Fc variants with altered binding to FcRn
CA2720365C (en) 2008-04-02 2019-01-15 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
CN102046195A (en) 2008-04-02 2011-05-04 宏观基因有限公司 HER2/neu-specific antibodies and methods of using same
JP5972573B2 (en) 2008-05-29 2016-08-17 ギャラクシー バイオテック， エルエルシー Monoclonal antibodies against basic fibroblast growth factor
NZ592611A (en) * 2008-10-10 2013-01-25 Emergent Product Dev Seattle A single chain fusion protein that binds to tcr complex and does not induce or induces a minimally detectable cytokine release
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
MX2011000455A (en) 2008-11-07 2011-02-25 Galaxy Biotech Llc Monoclonal antibodies to fibroblast growth factor receptor 2.
WO2010065921A2 (en) * 2008-12-05 2010-06-10 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
EP2400981A4 (en) * 2009-02-26 2013-02-27 Lpath Inc Humanized platelet activating factor antibody design using anti-lipid antibody templates
TWI559930B (en) 2009-04-16 2016-12-01 Abbvie Biotherapeutics Inc Anti-tnf-α antibodies and their uses
WO2010121093A2 (en) * 2009-04-17 2010-10-21 Lpath, Inc. Humanized antibody compositions and methods for binding lysophosphatidic acid
BRPI1012321A8 (en) 2009-06-17 2016-09-27 Abbott Biotherapeutics Corp ANTI-VEGF ANTIBODIES AND THEIR USES
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
IN2012DN03025A (en) 2009-09-09 2015-07-31 Ct Se Llc
US9096877B2 (en) 2009-10-07 2015-08-04 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
TWI483736B (en) 2009-10-23 2015-05-11 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
CN102753580A (en) 2009-10-28 2012-10-24 亚培生物医疗股份有限公司 Anti-egfr antibodies and their uses
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
EP3141260B1 (en) * 2009-11-30 2019-08-14 Janssen Biotech, Inc. Antibody fc mutants with ablated effector functions
US8937159B2 (en) 2009-12-16 2015-01-20 Abbvie Biotherapeutics Inc. Anti-HER2 antibodies and their uses
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
SG183847A1 (en) 2010-03-04 2012-10-30 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US8642557B2 (en) 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses
RU2613886C2 (en) 2010-06-03 2017-03-21 Дженентек, Инк. Antibodies and immunoconjugates rendered by immuno-positron emission tomography, methods of application
ES2667100T3 (en) 2010-08-02 2018-05-09 Macrogenics, Inc. Covalent Diabodies and Their Uses
UA112062C2 (en) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх CD33-Binding Agent
KR101993921B1 (en) 2010-12-06 2019-06-28 시애틀 지네틱스, 인크. Humanized antibodies to liv-1 and use of same to treat cancer
WO2012130831A1 (en) 2011-03-29 2012-10-04 Roche Glycart Ag Antibody fc variants
US10654916B2 (en) 2011-04-21 2020-05-19 The Regents Of The University Of California, A California Corporation Compositions and methods for the treatment of neuromyelitis optica
RU2632647C2 (en) 2011-04-22 2017-10-06 Аптево Рисерч Энд Девелопмент Ллс Proteins binding specific membrane prostate antigen, and related compositions and methods
EP2714079B2 (en) 2011-05-21 2019-08-28 MacroGenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
SG195072A1 (en) * 2011-05-21 2013-12-30 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
JP6094486B2 (en) 2011-08-11 2017-03-15 小野薬品工業株式会社 A therapeutic agent for autoimmune diseases comprising a PD-1 agonist
ES2937409T3 (en) 2011-10-28 2023-03-28 Prothena Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
EP2807188B1 (en) 2012-01-27 2019-09-11 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
RU2673153C2 (en) 2012-04-20 2018-11-22 АПТЕВО РИСЁРЧ ЭНД ДИВЕЛОПМЕНТ ЭлЭлСи Polypeptides binding to cd3
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
MA37794B1 (en) 2012-07-13 2017-07-31 Roche Glycart Ag Anti-vegf / anti-ang-2 bispecific antibodies and their use in the treatment of ocular vascular pathologies
JP2015537190A (en) 2012-09-19 2015-12-24 アッヴィ・バイオセラピューティクス・インコーポレイテッド Methods for identifying antibodies with reduced immunogenicity
UA118441C2 (en) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Antibodies recognizing alpha-synuclein
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
EA035943B1 (en) 2013-03-13 2020-09-03 Протена Биосайенсес Лимитед Antibody binding to human tau protein
EP2968520B1 (en) 2013-03-14 2021-05-12 MacroGenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
JP2016514690A (en) 2013-03-15 2016-05-23 アッヴィ バイオテクノロジー リミテッド Anti-CD25 antibodies and their use
MX2015012551A (en) 2013-03-15 2016-10-26 Abbvie Biotechnology Ltd Anti-cd25 antibodies and their uses.
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
KR102216088B1 (en) 2013-07-25 2021-02-15 싸이톰스 테라퓨틱스, 인크. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
UA116479C2 (en) 2013-08-09 2018-03-26 Макродженікс, Інк. Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP3041513B1 (en) 2013-09-08 2020-08-05 Kodiak Sciences Inc. Factor viii zwitterionic polymer conjugates
WO2015075635A2 (en) 2013-11-19 2015-05-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
LT3079719T (en) 2013-12-09 2019-12-10 Allakos Inc Anti-siglec-8 antibodies and methods of use thereof
US10675352B2 (en) 2014-02-14 2020-06-09 Centrose, Llc Extracellular targeted drug conjugates
EP4014995A1 (en) 2014-02-28 2022-06-22 Allakos Inc. Methods and compositions for treating siglec-8 associated diseases
US10407506B2 (en) 2014-03-12 2019-09-10 Prothena Biosciences Limited Anti-MCAM antibodies and associated methods of use
EP3116907A1 (en) 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
TW201623331A (en) 2014-03-12 2016-07-01 普羅帝納生物科學公司 Anti-MCAM antibodies and associated methods of use
US20170158755A1 (en) 2014-03-12 2017-06-08 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
US20170002077A1 (en) 2014-03-13 2017-01-05 Prothena Biosciences Limited Combination treatment for multiple sclerosis
EP3129051A1 (en) 2014-04-08 2017-02-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN107108738A (en) 2014-07-25 2017-08-29 西托姆克斯治疗公司 Anti-cd 3 antibodies, it anti-cd 3 antibodies, polyspecific anti-cd 3 antibodies, polyspecific can be activated can activate anti-cd 3 antibodies and its application method
WO2016036918A1 (en) 2014-09-03 2016-03-10 Boehringer Ingelheim International Gmbh Compound targeting il-23a and tnf-alpha and uses thereof
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
CN107108721B (en) 2014-09-29 2021-09-07 杜克大学 Bispecific molecules comprising an HIV-1 envelope targeting arm
WO2016061562A2 (en) 2014-10-17 2016-04-21 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
EP3212668B1 (en) 2014-10-31 2020-10-14 AbbVie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
HUE052526T2 (en) 2014-11-21 2021-05-28 Bristol Myers Squibb Co Antibodies comprising modified heavy constant regions
TWI758928B (en) 2014-11-21 2022-03-21 美商必治妥美雅史谷比公司 Antibodies against cd73 and uses thereof
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CA2971732A1 (en) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
TWI718122B (en) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 Anti-transthyretin antibodies
TWI781507B (en) 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 Anti-transthyretin antibodies
TWI769570B (en) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 Anti-transthyretin antibodies
US10722592B2 (en) 2015-03-18 2020-07-28 Seattle Genetics, Inc. CD48 antibodies and conjugates thereof
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
KR20170140318A (en) 2015-04-29 2017-12-20 리제너론 파마슈티칼스 인코포레이티드 Treatment of advanced ossificant fibrous dysplasia
LT3303396T (en) 2015-05-29 2023-01-10 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
TW201709932A (en) 2015-06-12 2017-03-16 西雅圖遺傳學公司 CD123 antibodies and conjugates thereof
CA2987797A1 (en) 2015-06-17 2016-12-22 Christopher Robert Bebbington Methods and compositions for treating fibrotic diseases
PL3316909T3 (en) 2015-06-30 2023-11-20 Seagen Inc. Anti-ntb-a antibodies and related compositions and methods
GB201513033D0 (en) * 2015-07-23 2015-09-09 Ucb Biopharma Sprl Proteins
JP2018530540A (en) 2015-09-16 2018-10-18 プロセナ バイオサイエンシーズ リミテッド Use of anti-MCAM antibodies for the treatment or prevention of giant cell arteritis, polymyalgia rheumatica or Takayasu arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
EA201890613A1 (en) 2015-09-21 2018-10-31 Аптево Рисёрч Энд Девелопмент Ллс POLYPEPTIDES CONNECTING CD3
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
CN109195626B (en) 2015-10-30 2022-09-13 银河生物技术有限责任公司 Antibodies that bind to death receptor 4 and death receptor 5
WO2017079369A2 (en) * 2015-11-03 2017-05-11 Glaxosmithkline Llc Novel antibodies
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
US11066465B2 (en) 2015-12-30 2021-07-20 Kodiak Sciences Inc. Antibodies and conjugates thereof
CA3013551A1 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Clec9a binding agents and use thereof
US20170233484A1 (en) 2016-02-17 2017-08-17 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
US20190284293A1 (en) 2016-03-04 2019-09-19 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017180813A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
WO2017189483A1 (en) 2016-04-25 2017-11-02 The Johns Hopkins University Znt8 assays for drug development and pharmaceutical compositions
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
US10752679B2 (en) 2016-05-02 2020-08-25 Prothena Biosciences Limited Tau immunotherapy
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
KR102417687B1 (en) 2016-05-09 2022-07-07 브리스톨-마이어스 스큅 컴퍼니 TL1A antibodies and uses thereof
EP3464362B1 (en) 2016-05-27 2020-12-09 AbbVie Biotherapeutics Inc. Anti-4-1bb antibodies and their uses
CN109476750B (en) 2016-05-27 2022-02-01 艾伯维生物制药股份有限公司 anti-CD 40 antibodies and uses thereof
BR112018074453A2 (en) 2016-05-27 2019-03-19 Abbvie Biotherapeutics Inc. bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
RU2769282C2 (en) 2016-06-20 2022-03-30 Кимаб Лимитед Anti-pd-l1 and il-2 cytokines
JP7017013B2 (en) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド Anti-transthyretin antibody
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7016470B2 (en) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド Anti-transthyretin antibody
PE20191102A1 (en) 2016-09-14 2019-08-23 Abbvie Biotherapeutics Inc ANTI-PD-1 ANTIBODIES AND THEIR USES
MX2019003225A (en) * 2016-09-21 2019-06-10 Aptevo Res & Development Llc Cd123 binding proteins and related compositions and methods.
TWI734879B (en) 2016-12-15 2021-08-01 美商艾伯維生物醫療股份有限公司 Anti-ox40 antibodies and their uses
JP2020505955A (en) 2017-02-06 2020-02-27 オリオンズ バイオサイエンス インコーポレイテッド Targeted modified interferon and uses thereof
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
CN110881274A (en) 2017-05-02 2020-03-13 普罗塞纳生物科学有限公司 Antibodies recognizing TAU
CN110831628A (en) 2017-05-05 2020-02-21 爱乐科斯公司 Methods and compositions for treating allergic eye diseases
KR20200013241A (en) 2017-05-25 2020-02-06 브리스톨-마이어스 스큅 컴퍼니 Antibodies Containing Modified Heavy Chain Constant Regions
EP3652540A4 (en) 2017-07-12 2021-04-07 The Johns Hopkins University A proteoliposome-based znt8 self-antigen for type 1 diabetes diagnosis
WO2019025299A1 (en) 2017-07-31 2019-02-07 F. Hoffmann-La Roche Ag Three-dimensional structure-based humanization method
JP2021502955A (en) 2017-09-28 2021-02-04 プロセナ・バイオサイエンシズ・リミテッド Administration regimen for the treatment of synuclein disease
CN111201244A (en) 2017-10-12 2020-05-26 学校法人庆应义塾 anti-AQP 3 monoclonal antibodies that specifically bind to the extracellular domain of aquaporin 3(AQP3) and uses thereof
TW202340257A (en) 2018-02-09 2023-10-16 日商小野藥品工業股份有限公司 Bispecific antibody
WO2019195561A2 (en) 2018-04-06 2019-10-10 BioLegend, Inc. Anti-tetraspanin 33 agents and compositions and methods for making and using the same
BR112020023118A2 (en) 2018-05-14 2021-04-13 Werewolf Therapeutics, Inc. ACTIVE ACTIVABLE INTERLEUKIN POLYPEPTIDS 12 AND METHODS OF USE OF THESE
KR20210021467A (en) 2018-05-14 2021-02-26 웨어울프 세라퓨틱스, 인크. Activatable interleukin-2 polypeptide and method of use thereof
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
CN113365697A (en) 2018-09-25 2021-09-07 百进生物科技公司 anti-TLR9 agents and compositions and methods of making and using the same
AU2019347751A1 (en) 2018-09-27 2021-04-29 Xilio Development, Inc. Masked cytokine polypeptides
WO2020076977A2 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
AU2019356573A1 (en) 2018-10-11 2021-05-27 Inhibrx, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
EP3863721A1 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. 5t4 single domain antibodies and therapeutic compositions thereof
TW202028246A (en) 2018-10-11 2020-08-01 美商英伊布里克斯公司 B7h3 single domain antibodies and therapeutic compositions thereof
EA202190986A1 (en) 2018-11-26 2021-12-14 Фоти Севен, Инк. HUMANIZED ANTIBODIES TO c-Kit
WO2020112870A1 (en) 2018-11-28 2020-06-04 Forty Seven, Inc. Genetically modified hspcs resistant to ablation regime
EP3887397A1 (en) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
MX2021007768A (en) 2018-12-26 2021-08-24 Xilio Dev Inc Anti-ctla4 antibodies and methods of use thereof.
AU2020219732A1 (en) 2019-02-05 2021-08-05 Seagen Inc. Anti-CD228 antibodies and antibody-drug conjugates
PE20212324A1 (en) 2019-03-03 2021-12-14 Prothena Biosciences Ltd ANTIBODIES THAT RECOGNIZE TAU
WO2020213084A1 (en) 2019-04-17 2020-10-22 Keio University Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
CA3137512A1 (en) 2019-05-14 2020-11-19 Werewolf Therapeutics, Inc. Separation moieties and methods and use thereof
JPWO2020250940A1 (en) 2019-06-11 2020-12-17
JP7295283B2 (en) 2019-06-25 2023-06-20 ギリアード サイエンシーズ， インコーポレイテッド FLT3L-FC fusion proteins and methods of use
AR120147A1 (en) 2019-10-04 2022-02-02 Seattle Genetics Inc ANTI-PD-L1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN113005088A (en) * 2019-12-19 2021-06-22 苏州方德门达新药开发有限公司 Engineered T cells, their preparation and use
WO2021142191A1 (en) 2020-01-08 2021-07-15 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
CA3164037A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
CN115427447A (en) 2020-01-17 2022-12-02 百进生物科技公司 anti-TLR 7 agents and compositions and methods of making and using the same
EP4114860A1 (en) 2020-03-06 2023-01-11 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
JP2023520771A (en) 2020-03-26 2023-05-19 シージェン インコーポレイテッド Methods of treating multiple myeloma
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
MX2022015157A (en) 2020-06-02 2023-01-16 Arcus Biosciences Inc Antibodies to tigit.
MX2023000949A (en) 2020-07-23 2023-02-22 Othair Prothena Ltd Anti-abeta antibodies.
CA3189225A1 (en) 2020-08-04 2022-02-10 Seagen Inc. Anti-cd228 antibodies and antibody-drug conjugates
PE20231105A1 (en) 2020-08-25 2023-07-19 Gilead Sciences Inc MULTI-SPECIFIC ANTIGEN-BINDING MOLECULES AGAINST HIV AND METHODS OF USE
TWI815194B (en) 2020-10-22 2023-09-11 美商基利科學股份有限公司 INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
AU2021376218A1 (en) 2020-11-08 2023-06-15 Seagen Inc. Combination Therapy
TW202237639A (en) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
TW202237638A (en) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
TW202302626A (en) 2021-02-15 2023-01-16 日商武田藥品工業股份有限公司 Cell therapy compositions and methods for modulating tgf-b signaling
US20220306743A1 (en) 2021-03-01 2022-09-29 Xilio Development, Inc. Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
JP2024508488A (en) 2021-03-01 2024-02-27 エクシリオ デベロップメント， インコーポレイテッド Combination of masked CTLA4 and PD1/PD-L1 antibodies to treat cancer
JP2024512324A (en) 2021-03-05 2024-03-19 ジーオー セラピューティクス，インコーポレイテッド Anti-glycoCD44 antibodies and their uses
IL305736A (en) 2021-03-09 2023-11-01 Xencor Inc Heterodimeric antibodies that bind cd3 and cldn6
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
WO2022217026A1 (en) 2021-04-09 2022-10-13 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
CA3228178A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
AU2022339667A1 (en) 2021-09-03 2024-04-11 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
WO2023034571A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-lamp1 antibodies and their uses
TW202327650A (en) 2021-09-23 2023-07-16 美商思進公司 Methods of treating multiple myeloma
WO2023215719A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
WO2024020051A1 (en) 2022-07-19 2024-01-25 BioLegend, Inc. Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
WO2024040114A2 (en) 2022-08-18 2024-02-22 BioLegend, Inc. Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US6129914A (en) * 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies

Also Published As

Publication number Publication date
DE69738984D1 (en) 2008-10-23
EP0966485A1 (en) 1999-12-29
EP0966485B1 (en) 2008-09-10
JP3947570B2 (en) 2007-07-25
CN1222162A (en) 1999-07-07
AU3208397A (en) 1997-12-09
US5834597A (en) 1998-11-10
AU725821B2 (en) 2000-10-19
WO1997044362A1 (en) 1997-11-27
PT966485E (en) 2008-12-10
CA2255826C (en) 2002-10-01
JP2002506420A (en) 2002-02-26
CN100549031C (en) 2009-10-14
ES2313736T3 (en) 2009-03-01
JP2007106771A (en) 2007-04-26
EP0966485A4 (en) 2005-01-19
ATE407952T1 (en) 2008-09-15

Similar Documents

Publication Publication Date Title
CA2255826A1 (en) Mutated nonactivating igg2 domains and anti-cd3 antibodies incorporating the same
DE69531679D1 (en) FOR E-SELECTIN AND P-SELECTIN-SPECIFIC CROSS-REACTIVE MONOCLONAL ANTIBODIES
EP1298144A3 (en) Murine monoclonal anti-idiotype antibody 3H1
CA2172376A1 (en) Antibodies to cd40
IE85350B1 (en) Human notch and delta, binding domains in toporythmic¹proteins, and methods based thereon
CA2429027A1 (en) Antibodies against human receptor h4-1bb
EP1135415A4 (en) Humanized antibodies to gamma-interferon
AU7566991A (en) Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
EP0687183A4 (en) Synergistic composition of cd4-based protein and anti-hiv-1 antibody, and methods of using same
AU6113396A (en) Novel high affinity human antibodies to tumor antigens
DE69021953T2 (en) Enzyme immunoassay for antigens and solid phase that can be used for them.
NZ228837A (en) Tumour associated antigen and the monoclonal antibody reactive with it useful in diagnosing and treating cancer
PL325667A1 (en) Antibodies effective against fas
WO2002034290A3 (en) Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma
EP0749445A4 (en) Antibodies which bind the g-csf receptor extracellular domain and methods of treatment
EP0714510A4 (en) Natural killer cell-specific antigen and antibodies that identify the same
NO972522L (en) Monoclonal antibodies with immunosuppressive activity
FI954827A0 (en) Immune particles carrying anti-CD4 monoclonal antibodies and their use
AU3283693A (en) Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy
AU2828795A (en) Monoclonal antibodies for the reduction of anti-xenogeneic immune responses
DK0889907T3 (en) Monoclonal antibodies that bind human growth hormone (hGH)
Leung The isolation, characterization and metal ion binding properties of the α-subunit of bovine brain S-100a protein
AU1915395A (en) Antibodies which bind the g-csf receptor extracellular domain and methods of treatment

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170519